ALRN - Aileron Therapeutics reports positive proof-of-concept data from early-stage ALRN-6924 study in lung cancer

Aileron Therapeutics (ALRN) announces new clinical data from its ongoing Phase 1b trial demonstrating that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer ((SCLC)).The results are being featured at the 32nd EORTC-NCI-AACR Annual (ENA 2020) Symposium. As of August 31, 2020, the data cut-off, a total of 26 adult patients were enrolled. 18 patients were enrolled across three ALRN-6924 dose levels (1.2 mg/kg, 0.6 mg/kg and 0.3 mg/kg) and an additional 8 patients were enrolled in a 0.3 mg/kg expansion cohort. ALRN-6924 was administered 24 hours before each dose of topotecan. Across all ALRN-6924 dose levels, Grade 3/4 anemia, Grade 3/4 thrombocytopenia and Grade 4 neutropenia (defined as <500/µL) were limited to 24%, 36% and 48% of patients, respectively.In the topotecan plus placebo arm of a recent third-party randomized Phase 2 trial in SCLC

For further details see:

Aileron Therapeutics reports positive proof-of-concept data from early-stage ALRN-6924 study in lung cancer